MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Harshavardhan PanigrahiDesignation :- Company Secretary and Compliance Officer Marksans Pharma Ltd - 524404 - Closure of Trading Window
In terms of the Company's Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading)(Amendment) Regulations, 2018, the trading window for dealing in the securities of Marksans Pharma Limited (the Company) for the insiders of the Company has been closed with effect from Wednesday, 1st January, 2020 till 48 hours after the declaration of financial results for the quarter ended 31st December, 2019. The date of declaration of financial results will be intimated separately in due course of time. MARKSANS PHARMA LTD. - 524404 - Clarification
With reference to Movement in Volume, Marksans Pharma Ltd has submitted to BSE a copy of Clarification is enclosed. Marksans Pharma Ltd - 524404 - Clarification sought from Marksans Pharma Ltd
The Exchange has sought clarification from Marksans Pharma Ltd on December 18, 2019, with reference to Movement in Volume.The reply is awaited. MARKSANS PHARMA LTD. - 524404 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosures of related party transactions for the half year ended 30th September, 2019. The financial results for the quarter and half year ended 30th September, 2019 both standalone and consolidated were published on 12th November, 2019. MARKSANS PHARMA LTD. - 524404 - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2019 And Limited Review Reports Thereon.
In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Unaudited Financial Results for the quarter and half year ended September 30, 2019 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. November 12, 2019 along with Limited Review Reports thereon. The meeting commenced at 12:30 p.m. and concluded at 02:05 p.m. Also attached is Press Release and Investor Presentation along with the Results. MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Notice Of Board Meeting
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2019 ,inter alia, to consider and approve This is to inform you that the Meeting of the Board of Directors of the Company will be held on Tuesday, 12th November, 2019 at Mumbai, to consider and approve the Unaudited Financial Results of the Company (both Standalone and Consolidated) for the quarter and half year ended 30th September, 2019. Marksans Pharma Ltd - 524404 - Intimation With Respect To Redemption Of Unlisted Preference Shares Of The Company.
We wish to inform you that the Company has redeemed 7% Redeemable Cumulative Preference Shares of Rs. 100/- each face value (Preference Shares) partly at par, on 30th October, 2019. Marksans Pharma Ltd - 524404 - Shareholding for the Period Ended September 30, 2019
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here MARKSANS PHARMA LTD. - 524404 - Shareholding for the Period Ended September 30, 2019
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here